Trial reportNeurology2012
A randomized trial of stress management for the prevention of new brain lesions in MS.
Trial report in Neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of the Effects of Stress Management on Neuroimaging, Clinical, Immune and Psychosocial Outcomes
A Randomized, Placebo-Controlled Study of Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Symptom changes in multiple sclerosis following psychological interventions: a systematic review.BMC neurology · 2014Pooled it
- Mindfulness based interventions in multiple sclerosis--a systematic review.BMC neurology · 2014Pooled it
- Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Trial
- A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis.BMC psychiatry · 2016Trial
- The effects of progressive muscular relaxation as a nursing procedure used for those who suffer from stress due to multiple sclerosis.Revista latino-americana de enfermagem · 2016Trial
- Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis.Psychosomatic medicine · 2013Trial
- Guided Imagery Improves Mood, Fatigue, and Quality of Life in Individuals With Multiple Sclerosis: An Exploratory Efficacy Trial of Healing Light Guided Imagery.Journal of evidence-based integrative medicineTrial
- Preventive strategies in neuroimmunology.Neurological research and practice · 2026Review
- Affective reserve in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- A single-arm, open-label pilot study of neuroimaging, behavioral, and peripheral inflammatory correlates of mindfulness-based stress reduction in multiple sclerosis.Scientific reports · 2024Observational
- Stressful life events and depression and fatigue in people with multiple sclerosis: a cross-sectional analysis of an international cohort.Acta neurologica Belgica · 2024Article
- Effects of Psychological Stress on Multiple SclerosisCNS & neurological disorders drug targets · 2024Review
- Acceptability of a digital health application to empower persons with multiple sclerosis with moderate to severe disability: single-arm prospective pilot study.BMC neurology · 2023Article
- Similar neural pathways link psychological stress and brain-age in health and multiple sclerosis.iScience · 2023Article
- Resilience, Stress, Well-Being, and Sleep Quality in Multiple Sclerosis.Journal of clinical medicine · 2023Article
- The impact of the COVID-19 pandemic on physical therapy practice for people with multiple sclerosis: A multicenter survey study of the RIMS network.Multiple sclerosis and related disorders · 2022Article
- Central stress processing, T-cell responsivity to stress hormones and disease severity in multiple sclerosis.Brain communications · 2022Article
- Experiences of persons with Multiple Sclerosis with lifestyle adjustment-A qualitative interview study.PloS one · 2022Article
- 'That would have been the perfect thing after diagnosis': development of a digital lifestyle management application in multiple sclerosis.Therapeutic advances in neurological disorders · 2022Article
- Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.Journal of personalized medicine · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThis trial examined the efficacy of a stress management program in reducing neuroimaging markers of multiple sclerosis (MS) disease activity.
methodsA total of 121 patients with relapsing forms of MS were randomized to receive stress management therapy for MS (SMT-MS) or a wait-list control condition. SMT-MS provided 16 individual treatment sessions over 24 weeks, followed by a 24-week post-treatment follow-up. The primary outcome was the cumulative number of new gadolinium-enhancing (Gd+) brain lesions on MRI at weeks 8, 16, and 24. Secondary outcomes included new or enlarging T2 MRI lesions, brain volume change, clinical exacerbation, and stress.
resultsSMT-MS resulted in a reduction in cumulative Gd+ lesions (p = 0.04) and greater numbers of participants remained free of Gd+ lesions during the treatment (76.8% vs 54.7%, p = 0.02), compared to participants receiving the control treatment. SMT-MS also resulted in significantly reduced numbers of cumulative new T2 lesions (p = 0.005) and a greater number of participants remaining free of new T2 lesions (69.5% vs 42.7%, p = 0.006). These effects were no longer detectable during the 24-week post-treatment follow-up period.
conclusionsThis trial indicates that SMT-MS may be useful in reducing the development of new MRI brain lesions while patients are in treatment. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that SMT-MS, a manualized stress management therapy program, reduced the number of Gd+ lesions in patients with MS during a 24-week treatment period. This benefit was not sustained beyond 24 weeks, and there were no clinical benefits.
trial registrationClinicalTrials.gov, number NCT00147446.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.